| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | N Petrosillo | |
| M E Falagas | |||
| E Ioannidou | |||
| P433 | issue | 9 | |
| P304 | page(s) | 816-827 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Clinical Microbiology and Infection | Q15757285 |
| P1476 | title | Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies | |
| P478 | volume | 14 |
| Q35052517 | Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study |
| Q35796552 | Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period |
| Q34999880 | Antibiotic-resistant gram-negative bacterial infections in patients with cancer |
| Q38052855 | Antimicrobial resistance in internal medicine wards |
| Q50931629 | Antimicrobial susceptibility of non-fermenting Gram-negative isolates to isepamicin in a region with high antibiotic resistance. |
| Q38068604 | Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective |
| Q37838126 | Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter? |
| Q53714289 | Carbapenem Resistance: A Review. |
| Q43179104 | Colistin administration to pediatric and neonatal patients |
| Q45974680 | Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. |
| Q40657458 | Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. |
| Q28082041 | Colistin for lung infection: an update |
| Q33847509 | Colistin in the 21st century |
| Q37307919 | Colistin use in pediatric intensive care unit for severe nosocomial infections: experience of an university hospital |
| Q38048852 | Colistin: an update on the antibiotic of the 21st century |
| Q34554879 | Combination approaches to combat multidrug-resistant bacteria |
| Q38232199 | Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date |
| Q43127814 | Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection |
| Q40802708 | Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model |
| Q45981762 | Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. |
| Q34049982 | Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii |
| Q24618178 | Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria |
| Q33826400 | Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis |
| Q53707227 | Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. |
| Q44852902 | Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus |
| Q37869910 | Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. |
| Q90572960 | HAMLET, a protein complex from human milk has bactericidal activity and enhances the activity of antibiotics against pathogenic Streptococci |
| Q35977417 | High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. |
| Q40855475 | In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates. |
| Q40230660 | In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm. |
| Q35662086 | In Vivo Selection of Pan-Drug Resistant Acinetobacter baumannii during Antibiotic Treatment |
| Q92302869 | In vitro Pharmacodynamics and PK/PD in Animals |
| Q38495174 | In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam |
| Q41388208 | In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa |
| Q37220041 | In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. |
| Q39927085 | In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli |
| Q100634918 | In vivo bactericidal effect of colistin-linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia |
| Q91361864 | In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia |
| Q26751255 | Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria |
| Q36222127 | Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. |
| Q37933361 | Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model. |
| Q36310173 | Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection |
| Q37785545 | Multidrug-resistant Gram-negative infections: the use of colistin. |
| Q35002302 | Multidrug-resistant Gram-negative infections: what are the treatment options? |
| Q37643631 | New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease |
| Q37636150 | New information about the polymyxin/colistin class of antibiotics |
| Q52749378 | Optimization of a resazurin-based microplate assay for large-scale compound screenings against Klebsiella pneumoniae. |
| Q36363261 | Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria |
| Q36335694 | Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? |
| Q36911111 | Pharmacokinetics and pharmacodynamics of antibacterial agents |
| Q38613051 | Polymyxin B versus colistin: an update |
| Q35585019 | Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases |
| Q38953618 | Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis |
| Q41026343 | Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp. with well defined resistance mechanisms |
| Q34309445 | Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii |
| Q34057525 | Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections |
| Q92302901 | Rational Combinations of Polymyxins with Other Antibiotics |
| Q39190865 | Recent advances and perspectives in the design and development of polymyxins. |
| Q40986687 | Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis |
| Q36326740 | Searching for new strategies against biofilm infections: Colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus single- and double-species biofilms |
| Q41420121 | Sensitization of Gram-negative bacteria to rifampin and OAK combinations |
| Q43159930 | Survival or Safety: Balancing act with Colistin |
| Q40540884 | Synergistic Antipseudomonal Effects of Synthetic Peptide AMP38 and Carbapenems. |
| Q37036489 | Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model |
| Q37469403 | Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection |
| Q38126768 | Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems |
| Q44872584 | The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach? |
| Q37954711 | The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms |
| Q37704397 | Treatment of Acinetobacter infections |
| Q37516904 | Update on the treatment of Pseudomonas aeruginosa pneumonia |
| Q92302887 | Use of Colistin in Critically Ill Patients |
Search more.